Phio Pharmaceuticals announces Safety Monitoring Committee recommendation to advance INTASYL PH─762 skin cancer study
Phio Pharmaceuticals Corp, a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL siRNA gene silencing technology to eliminate cancer, announced that the Safety Monitoring Committee (SMC) recommended dose …